ResMed (RMD) 10-Q 1 May 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Mar. 31, 2014	Apr. 21, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'RESMED INC	'
Entity Central Index Key	'0000943819	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	140,330,978

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$938,563	$876,048
Accounts receivable, net of allowance for doubtful accounts of $9,469 and $9,912 at March 31, 2014 and June 30, 2013, respectively	337,572	318,349
Inventories (note 3)	164,888	145,847
Deferred income taxes	36,021	38,552
Income taxes receivable	7,730	8,910
Prepaid expenses and other current assets	79,128	61,143
Total current assets	1,563,902	1,448,849
Non-current assets:	'	'
Property, plant and equipment, net (note 4)	429,049	411,433
Goodwill and other intangible assets, net (note 6)	336,938	324,468
Deferred income taxes	23,009	20,053
Other assets	11,668	5,918
Total non-current assets	800,664	761,872
Total assets	2,364,566	2,210,721
Current liabilities:	'	'
Accounts payable	55,483	60,688
Accrued expenses	142,082	137,674
Deferred revenue	42,182	44,953
Income taxes payable	6,353	30,090
Deferred income taxes	774	627
Current portion of long-term debt (note 7)	18	300,017
Total current liabilities	246,892	574,049
Non-current liabilities:	'	'
Deferred income taxes	10,081	9,895
Deferred revenue	15,585	11,928
Long-term debt (note 7)	395,785	769
Income taxes payable	5,318	3,564
Total non-current liabilities	426,769	26,156
Total liabilities	673,661	600,205
Commitments and contingencies (note 12)	'	'
Stockholders' equity: (note 10)	'	'
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	'	'
Common stock, $0.004 par value, 350,000,000 shares authorized; 175,932,557 issued and 140,291,544 outstanding at March 31, 2014 and 174,038,766 issued and 142,012,753 outstanding at June 30, 2013	561	568
Additional paid-in capital	1,084,502	1,025,064
Retained earnings	1,727,789	1,576,641
Treasury stock, at cost, 35,641,013 shares at March 31, 2014, and 32,026,013 shares at June 30, 2013	-1,251,482	-1,083,845
Accumulated other comprehensive income	129,535	92,088
Total stockholders' equity	1,690,905	1,610,516
Total liabilities and stockholders' equity	$2,364,566	$2,210,721

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Consolidated Balance Sheets [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$9,469	$9,912
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	175,932,557	174,038,766
Common stock, shares outstanding	140,291,544	142,012,753
Treasury stock, shares held	35,641,013	32,026,013

Consolidated_Statements_Of_Inc

Consolidated Statements Of Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Consolidated Statements Of Income [Abstract]	'	'	'	'
Net revenue	$397,758	$383,581	$1,139,762	$1,099,850
Cost of sales	145,970	144,132	411,234	419,041
Gross profit	251,788	239,449	728,528	680,809
Operating expenses:	'	'	'	'
Selling, general and administrative	115,101	109,628	328,172	315,745
Research and development	29,530	31,189	86,430	88,735
Amortization of acquired intangible assets	2,459	2,533	7,325	7,671
Total operating expenses	147,090	143,350	421,927	412,151
Income from operations	104,698	96,099	306,601	268,658
Other income, net:	'	'	'	'
Interest income, net	6,015	8,078	19,182	25,047
Other, net	2,199	3,815	-1,340	3,587
Total other income, net	8,214	11,893	17,842	28,634
Income before income taxes	112,912	107,992	324,443	297,292
Income taxes	22,943	23,079	66,908	63,172
Net income	$89,969	$84,913	$257,535	$234,120
Basic earnings per share	$0.64	$0.59	$1.82	$1.64
Diluted earnings per share (note 2)	$0.63	$0.58	$1.78	$1.60
Dividend declared per share	$0.25	$0.17	$0.75	$0.51
Basic shares outstanding	140,959	143,293	141,774	143,049
Diluted shares outstanding	143,375	146,643	144,758	146,479

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Consolidated Statements Of Comprehensive Income [Abstract]	'	'	'	'
Net income	$89,969	$84,913	$257,535	$234,120
Other comprehensive income:	'	'	'	'
Foreign currency translation gain (loss) adjustments	50,612	-8,361	37,447	22,659
Comprehensive income	$140,581	$76,552	$294,982	$256,779

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income	$257,535	$234,120
Adjustment to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	53,631	58,621
Stock-based compensation costs	32,679	27,658
Impairment of cost-method investments	'	225
Foreign currency revaluation	-3,305	-5,728
Excess tax benefit from stock-based compensation arrangements	-11,388	-12,757
Changes in operating assets and liabilities, net of effect of acquisitions:	'	'
Accounts receivable, net	-12,873	-9,214
Inventories, net	-15,735	9,863
Prepaid expenses, net deferred income taxes and other current assets	-4,020	-3,881
Accounts payable, accrued expenses and other liabilities	-20,839	-20,006
Net cash provided by operating activities	275,685	278,901
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-54,210	-47,576
Patent registration costs	-5,691	-5,853
Business acquisitions, net of cash acquired	-3,172	-5,418
Investments in cost-method investments	-5,275	-1,558
Purchases of foreign currency options	-1,337	-595
(Payments)/Proceeds from exercise of foreign currency contracts	-2,466	9,485
Net cash used in investing activities	-72,151	-51,515
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock, net	15,624	49,883
Excess tax benefit from stock-based compensation arrangements	11,388	12,757
Purchases of treasury stock	-169,398	-115,339
Payment of business combination contingent consideration	-1,117	-1,641
Proceeds from borrowings, net of borrowing costs	507,838	90,000
Repayment of borrowings	-415,029	-176
Dividend paid	-106,387	-72,939
Net cash used in financing activities	-157,081	-37,455
Effect of exchange rate changes on cash	16,062	13,226
Net increase in cash and cash equivalents	62,515	203,157
Cash and cash equivalents at beginning of period	876,048	809,541
Cash and cash equivalents at end of period	938,563	1,012,698
Supplemental disclosure of cash flow information:	'	'
Income taxes paid, net of refunds	76,127	62,371
Interest paid	4,680	4,640
Fair value of assets acquired, excluding cash	2,257	5,970
Liabilities assumed	-829	-2,278
Goodwill on acquisition	3,227	13,876
Deferred payments	-1,483	'
Fair value of contingent consideration	'	-12,150
Total purchase price, excluding contingent consideration	$3,172	$5,418

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	(1)        Summary of Significant Accounting Policies
	Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.
	The condensed consolidated financial statements for the three and nine months ended March 31, 2014 and 2013 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2013.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	(2)        Earnings Per Share
	Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.
	Stock options of 381,837  and 312,848 for the three months ended March 31, 2014 and 2013,  and stock options of 254,958 and 193,269 for the nine months ended March 31, 2014 and 2013, were not included in the computation of diluted earnings per share as the effect of exercising these options would have been anti-dilutive.
	Basic and diluted earnings per share for the three and nine months ended March 31, 2014 and 2013 are calculated as follows (in thousands except per share data):
			Three Months Ended March 31,				Nine Months Ended March 31,
			2014		2013		2014		2013
		Numerator:
		Net Income, used in calculating diluted earnings per share	$	89,969	$	84,913	$	257,535	$	234,120
		Denominator:
		Basic weighted-average common shares outstanding		140,959		143,293		141,774		143,049
		Effect of dilutive securities:
		Stock options and restricted stock units		2,416		3,350		2,984		3,430
		Diluted weighted average shares		143,375		146,643		144,758		146,479
		Basic earnings per share	$	0.64	$	0.59	$	1.82	$	1.64
		Diluted earnings per share	$	0.63	$	0.58	$	1.78	$	1.60

Inventories

Inventories	9 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories	'
	(3)        Inventories
	Inventories were comprised of the following at March 31, 2014 and June 30, 2013 (in thousands):
			31-Mar-14		30-Jun-13
		Raw materials	$	54,562	$	46,841
		Work in progress		2,701		1,990
		Finished goods		107,625		97,016
		Total inventories	$	164,888	$	145,847

Property_Plant_And_Equipment

Property, Plant And Equipment	9 Months Ended
	Mar. 31, 2014
Property, Plant And Equipment [Abstract]	'
Property, Plant And Equipment	'
	(4)        Property, Plant and Equipment
	Property, plant and equipment were comprised of the following as of March 31, 2014 and June 30, 2013 (in thousands):
			31-Mar-14		30-Jun-13
		Machinery and equipment	$	194,277	$	165,782
		Computer equipment		125,176		109,657
		Furniture and fixtures		42,082		40,706
		Vehicles		3,811		3,282
		Clinical, demonstration and rental equipment		103,988		102,304
		Leasehold improvements		30,726		28,466
		Land		61,790		61,091
		Buildings		263,401		260,857
				825,251		772,145
		Accumulated depreciation and amortization		-396,202		-360,712
		Property, plant and equipment, net	$	429,049	$	411,433

CostMethod_Investments

Cost-Method Investments	9 Months Ended
	Mar. 31, 2014
Cost-Method Investments [Abstract]	'
Cost-Method Investments	'
	(5)        Cost-Method Investments
	The aggregate carrying amount of our cost-method investments at March 31, 2014 and June 30, 2013, was $9.3 million and $4.0 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.
	We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered.  We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows.  During the nine months ended March 31, 2014 and 2013, we recognized  $Nil  and $0.2 million, respectively, of impairment losses related to our cost-method investments.  We have determined that the fair value of our investments exceed their carrying values.
	The following table shows a reconciliation of the changes in our cost-method investments during the nine months ended March 31, 2014 and 2013 (in thousands):
			Nine Months Ended March 31,
			2014		2013
		Balance at the beginning of the period	$	4,000	$	2,250
		Investments		5,275		1,558
		Impairment of cost-method investments		-		-225
		Balance at the end of the period	$	9,275	$	3,583

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets, Net	9 Months Ended
	Mar. 31, 2014
Goodwill And Other Intangible Assets, Net [Abstract]	'
Goodwill And Other Intangible Assets, Net	'
	(6)      Goodwill and Other Intangible Assets, net
	Goodwill
	Changes in the carrying amount of goodwill for the nine months ended March 31, 2014, and 2013 were as follows (in thousands):
			Nine Months Ended March 31,
			2014		2013
		Balance at the beginning of the period	$	274,829	$	256,209
		Business acquisition		3,227		13,876
		Foreign currency translation adjustments		12,729		2,711
		Balance at the end of the period	$	290,785	$	272,796
	Other Intangible Assets
	Other intangible assets are comprised of the following as of March 31, 2014, and June 30, 2013 (in thousands):
			31-Mar-14		June 30, 2013
		Developed/core product technology	$	76,058	$	72,698
		Accumulated amortization		-52,602		-45,492
		Developed/core product technology, net		23,456		27,206
		Trade names		2,799		2,662
		Accumulated amortization		-2,689		-2,491
		Trade names, net		110		171
		Non-compete agreements		2,100		2,068
		Accumulated amortization		-1,626		-1,265
		Non compete agreements, net		474		803
		Customer relationships		24,643		22,291
		Accumulated amortization		-20,237		-17,095
		Customer relationships, net		4,406		5,196
		Patents		66,972		59,962
		Accumulated amortization		-49,265		-43,699
		Patents, net		17,707		16,263
		Total other intangibles, net	$	46,153	$	49,639
	Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology.  We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Mar. 31, 2014
Long-Term Debt [Abstract]	'
Long-Term Debt	'
	(7)        Long-Term Debt
	Long-term debt at March 31, 2014 and June 30, 2013 consists of the following (in thousands):
			31-Mar-14		June 30, 2013
		Current long-term debt	$	18	$	300,017
		Non-current long-term debt		395,785		769
		Total long-term debt	$	395,803	$	300,786
	Credit Facility
	On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries.
	The credit agreement provides a $700 million senior unsecured five-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional $300 million. The credit facility also includes a $25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At March 31, 2014, the interest rate that was being charged on the outstanding principal amount was 1.2%.  An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility.
	When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previous revolving credit facility with Union Bank, N.A and other lenders. On that repayment, the previous credit agreement, dated as of February 10, 2011, between us and lenders (including Union Bank, N.A., as administrative agent, swing line lender and L/C Issuer, HSBC Bank USA, National Association, as syndication agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank), was terminated and the commitments under the previous credit agreement were also terminated.
	Our obligations under the current credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC.
	At March 31, 2014, there was $395.0  million outstanding under the credit agreement.

Product_Warranties

Product Warranties	9 Months Ended
	Mar. 31, 2014
Product Warranties [Abstract]	'
Product Warranties	'
	(8)        Product Warranties
	Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the nine months ended March 31, 2014 and 2013 are as follows (in thousands):
			Nine Months Ended March 31,
			2014		2013
		Balance at the beginning of the period	$	16,011	$	17,018
		Warranty accruals for the period		2,839		7,120
		Warranty costs incurred for the period		-5,458		-7,999
		Foreign currency translation adjustments		216		98
		Balance at the end of the period	$	13,608	$	16,237

StockBased_Employee_Compensati

Stock-Based Employee Compensation	9 Months Ended
	Mar. 31, 2014
Stock-Based Employee Compensation [Abstract]	'
Stock-Based Employee Compensation	'
	(9)        Stock-Based Employee Compensation
	We measure the compensation expense of all stock-based awards at fair value on the grant date.  We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period.  We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.
	We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:
			Three Months Ended March 31,				Nine Months Ended March 31,
			2014		2013		2014		2013
		Stock options:
		Weighted average grant date fair value	$	-	$	10.72	$	10.9	$	10.01
		Weighted average risk-free interest rate		-		0.73%		1.44%		0.67%
		Expected option life in years		-		4.9		4.9		4.9
		Dividend yield		-		1.56%		2.06%		1.66%
		Expected volatility		-		32%		30%		32%
		ESPP purchase rights:
		Weighted average risk-free interest rate		0.08%		0.15%		0.08%		0.15%
		Expected option life in years		6 months		6 months		6 months		6 months
		Dividend yield		1.96%		1.67%		1.44% - 1.96%		1.67%
		Expected volatility		28%		27%		24% - 28%		27% - 30%
	During the nine months ended March 31, 2014 and 2013, we also granted performance restricted stock units (“PRSUs”), which contain a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a three-year period, up to a maximum amount to be issued under the award of 200% of the original grant. The weighted average fair value of PRSUs granted during the nine months ended March 31, 2014 and 2013 was estimated at $50.09 and $38.46 per PRSU, respectively, using a Monte-Carlo simulation valuation model.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	(10)      Stockholders’ Equity
	Common Stock.    On February 21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. This program canceled and replaced our previous share repurchase program authorized on August 24, 2011, under which we had repurchased 18.1 million shares. The 20 million shares the new program authorizes us to purchase are in addition to the shares we repurchased on or before February 21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February 21, 2014 have been executed in accordance with this program.
	During the three and nine months ended March 31, 2014, we repurchased 1.6 million and 3.6 million shares at a cost of $72.5 million and $167.6 million, respectively. Since the inception of our share repurchase programs and through March 31, 2014, we have repurchased a total of 35.6 million shares at a cost of $1.3 billion.  Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share.  At March 31, 2014, 19.1 million additional shares can be repurchased under the approved share repurchase program.
	Preferred Stock.    In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at March 31, 2014 and June 30, 2013.
	Stock Options and Restricted Stock Units.    We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”).  These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.
	At the annual meeting of our stockholders on November 13, 2013, our stockholders approved an amendment to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 8.3 million shares to 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at March 31, 2014 is 16.2  million.  The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards.  The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted).
	At March 31, 2014, there were $85.0 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.4 years.  The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at March 31, 2014 was $224.2 million and $101.0  million, respectively.  The aggregate intrinsic value of the options exercised during the nine months ended March 31, 2014 and 2013, was $59.8 million and $56.5 million, respectively.
	The following table summarizes option activity during the nine months ended March 31, 2014:
				Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	6,316,136	$	22.68	3.1
		Granted	161,005		48.56
		Exercised	-1,077,527		19.28
		Forfeited	-48,817		39.58
		Outstanding at end of period	5,350,797	$	24.00	2.7
		Exercise price range of granted options	46.15 - 51.25
		Options exercisable at end of period	4,288,065	$	21.13
	The following table summarizes the activity of restricted stock units during the nine months ended March 31, 2014:
				Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	2,633,407	$	33.25	1.4
		Granted	842,315		46.67
		Vested	-886,626		31.41
		Forfeited	-64,005		33.46
		Outstanding at end of period	2,525,091	$	38.37	1.5
	Employee Stock Purchase Plan (the “ESPP”).  Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year.  At March 31, 2014, the number of shares remaining available for future issuance under the ESPP is 1.9 million shares.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	(11)       Fair Value Measurements
	In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The hierarchies of inputs are as follows:
		·		Level 1:Input prices quoted in an active market for identical financial assets or liabilities;
		·		Level 2:Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and
		·		Level 3:Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.
	The following table summarizes our financial assets and liabilities, as at March 31, 2014 and June 30, 2013, using the valuation input hierarchy (in thousands):
				Level 1		Level 2		Level 3		Total
		Balances at March 31, 2014
		Foreign currency hedging instruments, net	$	-	$	-5,298	$	-	$	-5,298
		Business acquisition contingent consideration	$	-	$	-	$	-1,557	$	-1,557
		Balances at June 30, 2013
		Foreign currency hedging instruments, net	$	-	$	-7,000	$	-	$	-7,000
		Business acquisition contingent consideration	$	-	$	-	$	-7,779	$	-7,779
	We determine the fair value of our financial assets and liabilities as follows:
	Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.
	Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones.  Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.
	The following is a reconciliation of changes in the fair value of contingent consideration for the nine months ended March 31, 2014 (in thousands):
			Nine Months Ended March 31, 2014
		Balance at the beginning of the period	$	-7,779
		Changes in fair value included in operating income		5,210
		Payments		1,117
		Foreign currency translation adjustments		-105
		Balance at the end of the period	$	-1,557
	We did not have any significant non-financial assets or liabilities measured at fair value on March 31, 2014 or June 30, 2013.

Legal_Actions_And_Contingencie

Legal Actions And Contingencies	9 Months Ended
	Mar. 31, 2014
Legal Actions And Contingencies [Abstract]	'
Legal Actions And Contingencies	'
	(12)      Legal Actions and Contingencies
	Litigation
	In the normal course of business, we are subject to routine litigation incidental to our business.  While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.
	In March 2013, we filed parallel legal actions in the International Trade Commission, or ITC, and in U.S. district court against Taiwanese manufacturer APEX to stop the infringement of several ResMed patents.  In August 2013, the ITC entered a consent decree against APEX, ordering that it not import or sell after import products that infringe the claims of the patents that ResMed asserted against APEX.  Thereafter, APEX initiated inter partes review proceedings in the U.S. Patent and Trademark Office, challenging the validity of most of the claims asserted against APEX in the ITC.  The U.S. district court has stayed the litigation against APEX pending resolution of the inter partes review.  APEX also advised the ITC that it redesigned the accused products and requested that the ITC determine whether those products are subject to the consent decree.  The ITC has referred APEX’s request to an administrative law judge for an initial determination on the question of infringement.  The administrative law judge heard the request in March 2014, but has not yet rendered a decision. Therefore the matter is ongoing as to APEX.   However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.
	In June 2013, we filed a lawsuit in U.S. district court against Chinese manufacturer BMC Medical Co., Ltd and its U.S. distributor to stop the infringement of several ResMed patents.  In July 2013, we amended the district court lawsuit, and filed a parallel proceeding in the ITC.  The ITC initiated an investigation of BMC’s alleged infringement in August 2013, and that matter is proceeding.  The district court lawsuit has been stayed by the court pending the conclusion of the ITC proceeding.  An administrative law judge heard the investigation in April 2014, but has not yet rendered a decision. Therefore the matter is ongoing as to BMC.  However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.
	In November 2013, we obtained preliminary injunctions prohibiting APEX and BMC from marketing and selling certain products accused of patent infringement in Germany.  The orders, entered by the Munich District Court, prohibit APEX and BMC from selling those products without a further court order.  ResMed also filed separate actions seeking damages from each defendant.  APEX and BMC have informed the court that they will contest the injunctions and the actions for damages, although in April 2014, BMC announced it was not contesting infringement or validity of one of the several asserted patents.  Therefore the matters are ongoing as to APEX and BMC.  However, we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.
	Contingent Obligations Under Recourse Provisions
	We use independent leasing companies to provide financing to certain customers for the purchase of our products.  In some cases, we are contingently liable in the event of a customer default, to the leasing companies, within certain limits, for unpaid installment receivables transferred to the leasing companies.  The gross amount of receivables sold during the three months ended March 31, 2014 and 2013, amounted to $2.7 million and $0.3 million, respectively.  The maximum potential amount of contingent liability under these arrangements at March 31, 2014 and June 30, 2013 were $4.1 million, and $0.3 million, respectively.  The recourse liability recognized by us at March 31, 2014 and June 30, 2013, in relation to these arrangements was $0.4 million and $0.2 million, respectively.

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging Activities	9 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Activities [Abstract]	'
Derivative Instruments And Hedging Activities	'
	(13)      Derivative Instruments and Hedging Activities
	We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations.  We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows.  The terms of such foreign currency hedging contracts generally do not exceed three years.  The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars.  Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.
	We do not designate these foreign currency contracts as hedges.  We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income.  We do not enter into financial instruments for trading or speculative purposes.
	We held foreign currency instruments with notional amounts totaling $465.6 million and $462.1 million at March 31, 2014 and June 30, 2013, respectively, to hedge foreign currency fluctuations.  These contracts mature at various dates prior to March 31, 2017.
	The following table summarizes the amount and location of our derivative financial instruments as of March 31, 2014 and June 30, 2013 (in thousands):
			31-Mar-14		30-Jun-13		Balance Sheet Caption
		Foreign currency hedging instruments	$	6,391	$	1,350		Other assets - current
		Foreign currency hedging instruments		411		657		Other assets - non current
		Foreign currency hedging instruments		-12,100		-9,007		Accrued expenses
			$	-5,298	$	-7,000
	The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the nine months ended March 31, 2014 and March 31, 2013, respectively (in thousands):
			Gain /(Loss) Recognized				Income Statement Caption
			Nine Months Ended March 31,
			2014		2013
		Foreign currency hedging instruments	$	-2,085	$	6,713		Other, net
		Other foreign-currency-denominated transactions		470		-2,997		Other, net
			$	-1,615	$	3,716
	We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments.  We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Organization And Basis Of Presentation	'
	Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.
	The condensed consolidated financial statements for the three and nine months ended March 31, 2014 and 2013 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2013.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule Of Basic And Diluted Earnings Per Share	'
			Three Months Ended March 31,				Nine Months Ended March 31,
			2014		2013		2014		2013
		Numerator:
		Net Income, used in calculating diluted earnings per share	$	89,969	$	84,913	$	257,535	$	234,120
		Denominator:
		Basic weighted-average common shares outstanding		140,959		143,293		141,774		143,049
		Effect of dilutive securities:
		Stock options and restricted stock units		2,416		3,350		2,984		3,430
		Diluted weighted average shares		143,375		146,643		144,758		146,479
		Basic earnings per share	$	0.64	$	0.59	$	1.82	$	1.64
		Diluted earnings per share	$	0.63	$	0.58	$	1.78	$	1.60

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Schedule Of Inventories	'
			31-Mar-14		30-Jun-13
		Raw materials	$	54,562	$	46,841
		Work in progress		2,701		1,990
		Finished goods		107,625		97,016
		Total inventories	$	164,888	$	145,847

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	9 Months Ended
	Mar. 31, 2014
Property, Plant And Equipment [Abstract]	'
Components Of Property, Plant And Equipment	'
			31-Mar-14		30-Jun-13
		Machinery and equipment	$	194,277	$	165,782
		Computer equipment		125,176		109,657
		Furniture and fixtures		42,082		40,706
		Vehicles		3,811		3,282
		Clinical, demonstration and rental equipment		103,988		102,304
		Leasehold improvements		30,726		28,466
		Land		61,790		61,091
		Buildings		263,401		260,857
				825,251		772,145
		Accumulated depreciation and amortization		-396,202		-360,712
		Property, plant and equipment, net	$	429,049	$	411,433

CostMethod_Investments_Tables

Cost-Method Investments (Tables)	9 Months Ended
	Mar. 31, 2014
Cost-Method Investments [Abstract]	'
Schedule Of Reconciliation Of Changes In Cost-Method Investments	'
			Nine Months Ended March 31,
			2014		2013
		Balance at the beginning of the period	$	4,000	$	2,250
		Investments		5,275		1,558
		Impairment of cost-method investments		-		-225
		Balance at the end of the period	$	9,275	$	3,583

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets, Net (Tables)	9 Months Ended
	Mar. 31, 2014
Goodwill And Other Intangible Assets, Net [Abstract]	'
Schedule Of Changes In Carrying Amount Of Goodwill	'
			Nine Months Ended March 31,
			2014		2013
		Balance at the beginning of the period	$	274,829	$	256,209
		Business acquisition		3,227		13,876
		Foreign currency translation adjustments		12,729		2,711
		Balance at the end of the period	$	290,785	$	272,796
Schedule Of Other Intangible Assets	'
			31-Mar-14		June 30, 2013
		Developed/core product technology	$	76,058	$	72,698
		Accumulated amortization		-52,602		-45,492
		Developed/core product technology, net		23,456		27,206
		Trade names		2,799		2,662
		Accumulated amortization		-2,689		-2,491
		Trade names, net		110		171
		Non-compete agreements		2,100		2,068
		Accumulated amortization		-1,626		-1,265
		Non compete agreements, net		474		803
		Customer relationships		24,643		22,291
		Accumulated amortization		-20,237		-17,095
		Customer relationships, net		4,406		5,196
		Patents		66,972		59,962
		Accumulated amortization		-49,265		-43,699
		Patents, net		17,707		16,263
		Total other intangibles, net	$	46,153	$	49,639

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Mar. 31, 2014
Long-Term Debt [Abstract]	'
Schedule Of Long-Term Debt	'
			31-Mar-14		June 30, 2013
		Current long-term debt	$	18	$	300,017
		Non-current long-term debt		395,785		769
		Total long-term debt	$	395,803	$	300,786

Product_Warranties_Tables

Product Warranties (Tables)	9 Months Ended
	Mar. 31, 2014
Product Warranties [Abstract]	'
Schedule Of Changes In Liability For Warranty Costs	'
			Nine Months Ended March 31,
			2014		2013
		Balance at the beginning of the period	$	16,011	$	17,018
		Warranty accruals for the period		2,839		7,120
		Warranty costs incurred for the period		-5,458		-7,999
		Foreign currency translation adjustments		216		98
		Balance at the end of the period	$	13,608	$	16,237

StockBased_Employee_Compensati1

Stock-Based Employee Compensation (Tables)	9 Months Ended
	Mar. 31, 2014
Stock-Based Employee Compensation [Abstract]	'
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted	'
			Three Months Ended March 31,				Nine Months Ended March 31,
			2014		2013		2014		2013
		Stock options:
		Weighted average grant date fair value	$	-	$	10.72	$	10.9	$	10.01
		Weighted average risk-free interest rate		-		0.73%		1.44%		0.67%
		Expected option life in years		-		4.9		4.9		4.9
		Dividend yield		-		1.56%		2.06%		1.66%
		Expected volatility		-		32%		30%		32%
		ESPP purchase rights:
		Weighted average risk-free interest rate		0.08%		0.15%		0.08%		0.15%
		Expected option life in years		6 months		6 months		6 months		6 months
		Dividend yield		1.96%		1.67%		1.44% - 1.96%		1.67%
		Expected volatility		28%		27%		24% - 28%		27% - 30%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Schedule Of Option Activity	'
				Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	6,316,136	$	22.68	3.1
		Granted	161,005		48.56
		Exercised	-1,077,527		19.28
		Forfeited	-48,817		39.58
		Outstanding at end of period	5,350,797	$	24.00	2.7
		Exercise price range of granted options	46.15 - 51.25
		Options exercisable at end of period	4,288,065	$	21.13
Schedule Of Activity Of Restricted Stock Units	'
				Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	2,633,407	$	33.25	1.4
		Granted	842,315		46.67
		Vested	-886,626		31.41
		Forfeited	-64,005		33.46
		Outstanding at end of period	2,525,091	$	38.37	1.5

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Summary Of Financial Assets And Liabilities	'
				Level 1		Level 2		Level 3		Total
		Balances at March 31, 2014
		Foreign currency hedging instruments, net	$	-	$	-5,298	$	-	$	-5,298
		Business acquisition contingent consideration	$	-	$	-	$	-1,557	$	-1,557
		Balances at June 30, 2013
		Foreign currency hedging instruments, net	$	-	$	-7,000	$	-	$	-7,000
		Business acquisition contingent consideration	$	-	$	-	$	-7,779	$	-7,779
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	'
			Nine Months Ended March 31, 2014
		Balance at the beginning of the period	$	-7,779
		Changes in fair value included in operating income		5,210
		Payments		1,117
		Foreign currency translation adjustments		-105
		Balance at the end of the period	$	-1,557

Derivative_Instruments_And_Hed1

Derivative Instruments And Hedging Activities (Tables)	9 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Activities [Abstract]	'
Summary Of Amount And Location Of Derivative Financial Instruments	'
			31-Mar-14		30-Jun-13		Balance Sheet Caption
		Foreign currency hedging instruments	$	6,391	$	1,350		Other assets - current
		Foreign currency hedging instruments		411		657		Other assets - non current
		Foreign currency hedging instruments		-12,100		-9,007		Accrued expenses
			$	-5,298	$	-7,000
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	'
			Gain /(Loss) Recognized				Income Statement Caption
			Nine Months Ended March 31,
			2014		2013
		Foreign currency hedging instruments	$	-2,085	$	6,713		Other, net
		Other foreign-currency-denominated transactions		470		-2,997		Other, net
			$	-1,615	$	3,716

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Stock options not included in the computation of diluted earnings per share	381,837	312,848	254,958	193,269

Earnings_Per_Share_Schedule_Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net Income, used in calculating diluted earnings per share	$89,969	$84,913	$257,535	$234,120
Basic weighted-average common shares outstanding	140,959	143,293	141,774	143,049
Effect of dilutive securities, stock options and restricted stock units	2,416	3,350	2,984	3,430
Diluted weighted average shares	143,375	146,643	144,758	146,479
Basic earnings per share	$0.64	$0.59	$1.82	$1.64
Diluted earnings per share	$0.63	$0.58	$1.78	$1.60

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$54,562	$46,841
Work in progress	2,701	1,990
Finished goods	107,625	97,016
Total inventories	$164,888	$145,847

Property_Plant_And_Equipment_D

Property, Plant And Equipment (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$825,251	$772,145
Accumulated depreciation and amortization	-396,202	-360,712
Property, plant and equipment, net	429,049	411,433
Machinery And Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	194,277	165,782
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	125,176	109,657
Furniture And Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	42,082	40,706
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	3,811	3,282
Clinical, Demonstration And Rental Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	103,988	102,304
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	30,726	28,466
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	61,790	61,091
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$263,401	$260,857

CostMethod_Investments_Narrati

Cost-Method Investments (Narrative) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2012
Cost-Method Investments [Abstract]	'	'	'	'
Aggregate carrying amount of cost-method investments	$3,583	$9,275	$4,000	$2,250
Write-down of cost-method investments	$225	'	'	'

CostMethod_Investments_Schedul

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cost-Method Investments [Abstract]	'	'
Balance at the beginning of the period	$4,000	$2,250
Investments	5,275	1,558
Impairment of cost-method investments	'	-225
Balance at the end of the period	$9,275	$3,583

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets, Net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Goodwill And Other Intangible Assets, Net [Abstract]	'	'
Balance at the beginning of the period	$274,829	$256,209
Business acquisition	3,227	13,876
Foreign currency translation adjustments	12,729	2,711
Balance at the end of the period	$290,785	$272,796

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets, Net (Schedule Of Other Intangible Assets) (Details) (USD $)

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

In Thousands, unless otherwise specified

Developed/Core Product Technology [Member]

Developed/Core Product Technology [Member]

Trade Names [Member]

Trade Names [Member]

Non Compete Agreements [Member]

Non Compete Agreements [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Patents [Member]

Patents [Member]

Minimum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other intangibles, gross

'

'

$76,058

$72,698

$2,799

$2,662

$2,100

$2,068

$24,643

$22,291

$66,972

$59,962

'

'

Accumulated amortization

'

'

-52,602

-45,492

-2,689

-2,491

-1,626

-1,265

-20,237

-17,095

-49,265

-43,699

'

'

Total other intangibles, net

$46,153

$49,639

$23,456

$27,206

$110

$171

$474

$803

$4,406

$5,196

$17,707

$16,263

'

'

Intangible assets, estimated useful life

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'9 years

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)	9 Months Ended
	Mar. 31, 2014	Oct. 31, 2013
Line of Credit Facility [Line Items]	'	'
Amount outstanding under credit facility	$395,000,000	'
Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility termination date	31-Oct-18	'
Interest rate on outstanding principal amount	1.20%	'
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Maximum borrowing capacity	'	700,000,000
Credit facility term, years	'5 years	'
Uncommitted option to increase credit facility	300,000,000	'
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Maximum borrowing capacity	'	$25,000,000
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Commitment fees percentage rate on unused portion of credit facility	0.15%	'
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility interest rate equal to reference rate plus	1.00%	'
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Commitment fees percentage rate on unused portion of credit facility	0.25%	'
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility interest rate equal to reference rate plus	2.00%	'

LongTerm_Debt_Schedule_Of_Long

Long-Term Debt (Schedule Of Long-Term Debt) (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Long-Term Debt [Abstract]	'	'
Current long-term debt	$18	$300,017
Non-current long-term debt	395,785	769
Total long-term debt	$395,803	$300,786

Product_Warranties_Details

Product Warranties (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Product Warranties [Abstract]	'	'
Balance at the beginning of the period	$16,011	$17,018
Warranty accruals for the period	2,839	7,120
Warranty costs incurred for the period	-5,458	-7,999
Foreign currency translation adjustments	216	98
Balance at the end of the period	$13,608	$16,237

StockBased_Employee_Compensati2

Stock-Based Employee Compensation (Narrative) (Details) (Performance Shares [Member], USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Performance Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shareholder return period	'3 years	'
Maximum amount of restricted stock units to be issued, percentage of the original grant	200.00%	'
Fair value of equity instruments other than options granted	$50.09	$38.46

StockBased_Employee_Compensati3

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average grant date fair value	'	$10.72	$10.90	$10.01
Weighted average risk-free interest rate	'	0.73%	1.44%	0.67%
Expected option life in years	'0 years	'4 years 10 months 24 days	'4 years 10 months 24 days	'4 years 10 months 24 days
Dividend yield	'	1.56%	2.06%	1.66%
Expected volatility	'	32.00%	30.00%	32.00%
ESPP Purchase Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average risk-free interest rate	0.08%	0.15%	0.08%	0.15%
Expected option life in years	'6 months	'6 months	'6 months	'6 months
Dividend yield	1.96%	1.67%	'	1.67%
Expected volatility	28.00%	27.00%	'	'
Expected volatility, minimum	'	'	24.00%	27.00%
Expected volatility, maximum	'	'	28.00%	30.00%
Minimum [Member] | ESPP Purchase Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Dividend yield	1.96%	'	1.44%	'
Maximum [Member] | ESPP Purchase Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Dividend yield	'	'	1.96%	'

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

30 Months Ended

139 Months Ended

0 Months Ended

9 Months Ended

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Feb. 20, 2014

Dec. 31, 2013

Feb. 21, 2014

Jun. 30, 2013

Apr. 30, 1997

Nov. 13, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized to be repurchased under repurchase program

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

Common shares repurchased

1,600,000

3,600,000

'

18,100,000

35,600,000

'

'

'

'

'

'

'

'

'

Cost of common shares repurchased

$72,500,000

$167,600,000

'

'

$1,300,000,000

'

'

'

'

'

'

'

'

'

Additional shares that can be repurchased under the approved share repurchase program

19,100,000

19,100,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

2,000,000

2,000,000

'

'

'

'

2,000,000

2,000,000

'

'

'

'

'

'

Preferred stock at par value

$0.01

$0.01

'

'

'

'

$0.01

$0.01

'

'

'

'

'

'

Preferred stock, shares issued

0

0

'

'

'

'

0

'

'

'

'

'

'

'

Preferred stock, shares outstanding

0

0

'

'

'

'

0

'

'

'

'

'

'

'

Stock option and restricted stock units expiration period

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

Stock options and restricted stock units vesting period

'

'

'

'

'

'

'

'

'

'

'1 year

'

'4 years

'

Number of additional shares authorized

'

'

'

'

'

'

'

'

8,300,000

'

'

'

'

'

Common stock authorized for issuance

43,700,000

43,700,000

'

'

'

'

'

'

'

'

'

'

'

'

Number of securities remaining available for future issuance

16,200,000

16,200,000

'

'

'

'

'

'

'

1,900,000

'

'

'

'

Reduction in the number of shares of common stock available for issuance

2.8

2.8

'

'

'

'

'

'

'

'

'

'

'

'

Maximum number of shares subject to awards granted

3,000,000

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock shares granted in participant's initial year of hiring

4,500,000

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to unvested stock-based compensation arrangements

85,000,000

85,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements

'

'2 years 4 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of the stock-based compensation arrangements outstanding

224,200,000

224,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of the stock-based compensation arrangements exercisable

101,000,000

101,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of the options exercised

'

59,800,000

56,500,000

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase program offering period

'

'

'

'

'

'

'

'

'

'

'

'3 months

'

'27 months

Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

Common stock shares subscribed

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

Stockholders_Equity_Schedule_O

Stockholders' Equity (Schedule Of Option Activity) (Details) (USD $)	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Outstanding at beginning of period	6,316,136	'
Options, Granted	161,005	'
Options, Exercised	-1,077,527	'
Options, Forfeited	-48,817	'
Options, Outstanding at end of period	5,350,797	6,316,136
Options exercisable at end of period	4,288,065	'
Weighted Average Exercise Price, Outstanding at beginning of period	$22.68	'
Weighted Average Exercise Price, Granted	$48.56	'
Weighted Average Exercise Price, Exercised	$19.28	'
Weighted Average Exercise Price, Forfeited	$39.58	'
Weighted Average Exercise Price, Outstanding at end of period	$24	$22.68
Weighted Average Exercise Price, Options exercisable at end of period	$21.13	'
Weighted Average Remaining Term to Vest in Years, Outstanding	'2 years 8 months 12 days	'3 years 1 month 6 days
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Exercise price range of granted options	$46.15	'
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Exercise price range of granted options	$51.25	'

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2013
Restricted Stock Units (RSUs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Restricted Stock Units, Outstanding at beginning of period	2,633,407	'
Restricted Stock Units, Granted	842,315	'
Restricted Stock Units, Vested	-886,626	'
Restricted Stock Units, Forfeited	-64,005	'
Restricted Stock Units, Outstanding at end of period	2,525,091	2,633,407
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$33.25	'
Weighted Average Grant-Date Fair Value, Granted	$46.67	'
Weighted Average Grant-Date Fair Value, Vested	$31.41	'
Weighted Average Grant-Date Fair Value, Forfeited	$33.46	'
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$38.37	$33.25
Weighted Average Remaining Contractual Term in Years, Outstanding	'1 year 6 months	'1 year 4 months 24 days

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	($5,298)	($7,000)
Business acquisition contingent consideration	-1,557	-7,779
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	'	'
Business acquisition contingent consideration	'	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	-5,298	-7,000
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business acquisition contingent consideration	($1,557)	($7,779)

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Balance at the beginning of the period	($7,779)
Changes in fair value included in operating income	5,210
Payments	1,117
Foreign currency translation adjustments	-105
Balance at the end of the period	($1,557)

Legal_Actions_And_Contingencie1

Legal Actions And Contingencies (Details) (Obligation to Repurchase Receivables Sold [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013
Obligation to Repurchase Receivables Sold [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Receivables sold to leasing companies under debt factoring arrangements	$2.70	$0.30	'
Maximum potential contingent liability	4.1	'	0.3
Recourse liability recognized	$0.40	'	$0.20

Derivative_Instruments_And_Hed2

Derivative Instruments And Hedging Activities (Narrative) (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2014
In Millions, unless otherwise specified			Foreign Currency Contracts [Member]
Derivative [Line Items]	'	'	'
Terms of foreign currency hedging contracts, maximum	'	'	'3 years
Notional amount of foreign currency hedging contracts held	$465.60	$462.10	'

Derivative_Instruments_And_Hed3

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) (Foreign Currency Contracts [Member], USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets (Liabilities)	($5,298)	($7,000)
Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets	6,391	1,350
Other Noncurrent Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets	411	657
Accrued Expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Liabilities	($12,100)	($9,007)

Derivative_Instruments_And_Hed4

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) (Derivatives Not Designated As Hedging Instruments [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized in Income	($1,615)	$3,716
Foreign Currency Contracts [Member] | Other, Net [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Foreign currency-hedging instruments	-2,085	6,713
Other Foreign-currency-denominated Transactions [Member] | Other, Net [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Other foreign-currency-denominated transactions	$470	($2,997)